Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) (TA845)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2014
Tocilizumab for treating giant cell arteritis (TA518)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 April 2018
Upadacitinib for treating giant cell arteritis ID6299Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC